- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Exploration With Blinatumomab and CAR T-Cell Therapy Continues in ALL
December 22nd 2019, 4:00pm
State of the Science Summit on Hematologic Malignancies
Joseph Wynne, MD, discusses ongoing studies with blinatumomab and CAR T-cell therapy in acute lymphoblastic leukemia, as well as the importance of assessing minimal residual disease in this space.
Novel Agents and Combos Continue to Transform Myeloma Paradigm
December 17th 2019, 12:32am
State of the Science Summit on Hematologic Malignancies
Agne Paner, MD, discusses the treatment paradigm in multiple myeloma and promising agents on the horizon.
Analysis Unable to Achieve Concordance Among PD-L1 Assays in TNBC
December 16th 2019, 2:53am
San Antonio Breast Cancer Symposium
Mathematical modeling was unable to harmonize the VENTANA SP263 and Dako 22C3 PD-L1 assays with the FDA-approved VENTANA PD-L1 SP142 companion diagnostic for the selection of patients with advanced triple-negative breast cancer appropriate for atezolizumab plus nab-paclitaxel.
Adjuvant Chemo Shows Slight Benefit in Younger Women With Breast Cancer Who Have Mixed Clinical, Genomic Risk
December 16th 2019, 1:06am
San Antonio Breast Cancer Symposium
Patients with premenopausal breast cancer and discordant clinical and genomic risk had a small increase in distant metastasis if they did not receive adjuvant chemotherapy, according to a post hoc analysis of the MINDACT trial.
Dr. Rugo on Updated Data From the SOPHIA Trial in HER2+ Metastatic Breast Cancer
December 14th 2019, 5:38am
San Antonio Breast Cancer Symposium
Hope S. Rugo, MD, discusses the updated data from the phase III SOPHIA trial for patients with HER2-positive metastatic breast cancer who had received prior anti-HER2 therapies, presented at the 2019 San Antonio Breast Cancer Symposium.
Neoadjuvant Olaparib Combo Safe in Breast Cancer
December 14th 2019, 5:00am
San Antonio Breast Cancer Symposium
Adding the PARP inhibitor olaparib to neoadjuvant platinum based-chemotherapy was determined to be a safe treatment for patients with triple-negative breast cancer, as well as for patients with breast cancer whose tumors harbor germline BRCA mutations.
Chemo-Free Regimen Matches Neoadjuvant Chemo in HR+/HER2- Breast Cancer
December 14th 2019, 3:59am
San Antonio Breast Cancer Symposium
Almost half of patients with high-risk luminal-B breast cancer converted to a low risk of recurrence following chemotherapy-free neoadjuvant therapy, matching the performance of standard chemotherapy in small randomized trial.
ctDNA and CTCs Potentially Poised to Predict Recurrence for Early TNBC
December 14th 2019, 2:05am
San Antonio Breast Cancer Symposium
The presence of circulating tumor DNA and circulating tumor cells following neoadjuvant chemotherapy can be an independent predictor of disease recurrence in patients with early triple-negative breast cancer.
Residual Cancer Burden Predicts Patient Outcomes Across Breast Cancer Subtypes
December 14th 2019, 1:22am
San Antonio Breast Cancer Symposium
Residual cancer burden after neoadjuvant chemotherapy has been shown to be an accurate long-term predictor of disease recurrence and survival across all breast cancer subtypes.
Oral Regimen for Paclitaxel Administration May Become Available in Breast Cancer
December 13th 2019, 11:39pm
San Antonio Breast Cancer Symposium
The addition of encequidar (HM30181A) to oral paclitaxel is the first oral taxane regimen to result in an improvement in overall response rates as compared with an intravenous administration of paclitaxel in patients with metastatic breast cancer.
Estrogen Decreases Breast Cancer Incidence in Postmenopausal Women, Estrogen Plus Progestin Has Opposite Effect
December 13th 2019, 11:28pm
San Antonio Breast Cancer Symposium
Estrogen alone as menopausal hormone therapy was found to decrease breast cancer incidence in postmenopausal women.
Dr. Pinilla Alba on Safety Findings of the PARTNER Trial in Breast Cancer
December 13th 2019, 11:05pm
San Antonio Breast Cancer Symposium
Karen Pinilla Alba, MD, discusses the safety findings stages 1 and 2 of the phase II/III PARTNER trial in triple negative and/or germline BRCA-mutated breast cancer.
Neoadjuvant Durvalumab Regimen Shows Promise in TNBC
December 13th 2019, 6:07pm
San Antonio Breast Cancer Symposium
A durvalumab-based neoadjuvant regimen induced an impressive pathologic complete response rate in patients with triple-negative breast cancer.
Dr. Lin on Impact of Neratinib on CNS Metastases in HER2+ Breast Cancer
December 13th 2019, 6:27am
San Antonio Breast Cancer Symposium
Nancy Lin, MD, discusses the impact of neratinib on development and progression of central nervous system metastases in patients with HER2-positive metastatic breast cancer.
Dr. Conte on the OlympiAD Trial in BRCA-Mutated HER2-Negative Breast Cancer
December 13th 2019, 6:25am
San Antonio Breast Cancer Symposium
Pierfranco Conte, MD, discusses the findings of the OlympiAD trial in BRCA-mutated HER2-negative metastatic breast cancer.
Accelerated Partial Breast Irradiation Could Replace Whole Breast Irradiation in Low-Risk Early Breast Cancer
December 13th 2019, 3:12am
San Antonio Breast Cancer Symposium
Accelerated partial breast irradiation using intensity-modulated radiotherapy is not significantly different from whole breast irradiation in preventing recurrence in patients with low-risk early breast cancer.
Extended Follow-Up Shows Continued Olaparib Benefit in BRCA+ MBC
December 13th 2019, 3:07am
San Antonio Breast Cancer Symposium
Olaparib continued to show a numerical overall survival (OS) benefit with a favorable hazard ratio for OS versus chemotherapy in patients with BRCA-positive, HER2-negative metastatic breast cancer, according to an extended, exploratory follow-up analysis of the phase III OlympiAD trial.
Dual Anti-HER2 Therapy Reduces Recurrence Risk
December 13th 2019, 2:37am
San Antonio Breast Cancer Symposium
A pathologic complete response to HER2-directed neoadjuvant therapy reduced the risk of recurrence in early HER2-positive breast cancer but did not eliminate it, supporting the common practice of continued anti-HER2 therapy.
Neoadjuvant Atezolizumab Regimen Slightly Improves pCR in TNBC
December 13th 2019, 2:11am
San Antonio Breast Cancer Symposium
Atezolizumab (Tecentriq) in combination with carboplatin and nab-paclitaxel (Abraxane) did not lead to a statistically significant increase in pathologic complete response (pCR) rate compared with carboplatin/nab-paclitaxel alone in patients with early high-risk and locally advanced triple-negative breast cancer,
Survival Benefit Hinted at With Durvalumab Maintenance in TNBC
December 13th 2019, 12:11am
San Antonio Breast Cancer Symposium
Maintenance durvalumab may improve outcomes versus chemotherapy in patients with triple-negative breast cancer or those with PD-L1–positive breast cancer across several subtypes, according to exploratory analyses from the phase II randomized SAFIR02-IMMUNO trial presented at the 2019 San Antonio Breast Cancer Symposium.